퀸스 테라퓨틱스(QNCX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $34.04 (+5.03%), 시가총액 $0.02B, 52주 범위 $0.08 ~ $4.40.
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprisin
퀸스 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
퀸스 테라퓨틱스의 현재 주가는 $34.04 (+5.03%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
퀸스 테라퓨틱스의 시가총액은 약 $0.02B입니다.
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candid